Literature DB >> 16581122

Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia.

Gabrielle S Sellick1, Daniel Catovsky, Richard S Houlston.   

Abstract

ARLTS1, a member of the Ras superfamily and putative tumor-suppressor gene resides at chromosome 13q14, a region commonly deleted in hematopoietic and solid tumors. Previously, the truncating single nucleotide polymorphism (SNP) of ARLTS, G446A (W149X) has been reported to act as a multi-site tumor susceptibility allele. To explore the relationship between polymorphic variation in ARTLS1 and risk of chronic lymphocytic leukemia (CLL) we analyzed germline DNA from 413 cases and 471 healthy controls for W149X and five additional coding SNPs, S99S, P131L, L132L, C148R, and E164K. A high proportion of the cases were familial, thereby empowering detection of an association. None of the SNPs were individually significantly associated with risk of CLL and there was no evidence for epistatic interaction between loci. Our study does not support the postulate that variants of ARLTS1 influence the risk of CLL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581122     DOI: 10.1016/j.leukres.2006.02.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

Review 2.  Familial chronic lymphocytic leukemia.

Authors:  Richard S Houlston; Daniel Catovsky
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

3.  The molecular basis of familial chronic lymphocytic leukemia.

Authors:  Dalemari Crowther-Swanepoel; Richard S Houlston
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

4.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

Review 5.  Inherited predisposition to chronic lymphocytic leukemia.

Authors:  Jennifer R Brown
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

6.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

Review 7.  ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Authors:  Yan Jiang; Chen-Yang Zhao; Li-Chun Cheng; Bing Xu; Hui-Yi Lv
Journal:  Hered Cancer Clin Pract       Date:  2017-06-13       Impact factor: 2.857

8.  ARLTS1 polymorphisms and basal cell carcinoma of the skin.

Authors:  Xuchen Li; Andreas Gast; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

9.  ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Authors:  Sanna Siltanen; Daniel Fischer; Tommi Rantapero; Virpi Laitinen; John Patrick Mpindi; Olli Kallioniemi; Tiina Wahlfors; Johanna Schleutker
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.